Mark Delong - Apellis Pharmaceuticals Chief Officer
| APLS Stock | USD 34.14 1.51 4.63% |
Executive
Mark Delong is Chief Officer of Apellis Pharmaceuticals
| Age | 47 |
| Address | 100 Fifth Avenue, Waltham, MA, United States, 02451 |
| Phone | 617 977 5700 |
| Web | https://www.apellis.com |
Mark Delong Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Delong against Apellis Pharmaceuticals stock is an integral part of due diligence when investing in Apellis Pharmaceuticals. Mark Delong insider activity provides valuable insight into whether Apellis Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Apellis Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Apellis Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Delong over three months ago Disposition of 5201 shares by Mark Delong of Apellis Pharmaceuticals at 13.85 subject to Rule 16b-3 |
Apellis Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.1623) % which means that it has lost $0.1623 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0656) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals' management efficiency ratios could be used to measure how well Apellis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.7 in 2024. Return On Capital Employed is likely to drop to -1 in 2024. At this time, Apellis Pharmaceuticals' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 205.1 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 18.2 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Emil MD | Terns Pharmaceuticals | 44 | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| JD Esq | Acumen Pharmaceuticals | 53 | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Julie Kirschling | Immunovant | N/A | |
| Linda Arsenault | Amylyx Pharmaceuticals | N/A | |
| Christina Rossi | Blueprint Medicines Corp | 47 | |
| Carole Huntsman | Madrigal Pharmaceuticals | 59 | |
| Lauren MBA | Immunovant | N/A | |
| Kianoush Motesharei | Madrigal Pharmaceuticals | ||
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Mark JD | Immunovant | 51 | |
Management Performance
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.16 |
Apellis Pharmaceuticals Leadership Team
Elected by the shareholders, the Apellis Pharmaceuticals' board of directors comprises two types of representatives: Apellis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Apellis. The board's role is to monitor Apellis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Apellis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Apellis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Sullivan, CFO, Treasurer | ||
| Cedric MD, President, CoFounder | ||
| Meredith Kaya, Investor President | ||
| Adam Townsend, Chief Commercial Officer | ||
| James CPA, Corporate VP | ||
| Karen Lewis, Chief Officer | ||
| Nur Nicholson, Chief Officer | ||
| JD Esq, General Counsel | ||
| MBA JD, CoFounder Director | ||
| Pr MD, Head Board | ||
| David Acheson, Senior Commercial | ||
| Lukas MD, Chief Officer | ||
| Mark Delong, Chief Officer | ||
| Federico MD, CoFounder Officer | ||
| Victoria Brown, Senior President | ||
| Pascal Deschatelets, CoFounder Officer | ||
| Caroline MD, Chief Officer | ||
| Jeffrey Eisele, Chief Officer |
Apellis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Apellis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.35) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 4.13 B | ||||
| Shares Outstanding | 124.39 M | ||||
| Shares Owned By Insiders | 13.98 % | ||||
| Shares Owned By Institutions | 98.75 % | ||||
| Number Of Shares Shorted | 23.18 M | ||||
| Price To Earning | (6.94) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.